热门资讯> 正文
ARCA生物制药批准1比12反向股权拆分
2024-08-24 05:37
- Pharmaceutical company ARCA biopharma (NASDAQ:ABIO) said on Friday its board has approved a reverse stock split of its shares at a ratio of 1-for-12.
- ARCA’s (ABIO) stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Global Market on September 3, 2024.
- The company’s stock will trade under the new name Oruka Therapeutics, and under the new symbol “ORKA” after the closing of its merger with Oruka.
- The reverse stock split is expected to reduce ARCA (ABIO)’s common shares from about 14.5M shares to about 1.2M shares.
- ARCA’s shares were down 3.85% during after-hours trading.
More on ARCA biopharma
- Financial information for ARCA biopharma
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
